JP2023552851A5 - - Google Patents
Info
- Publication number
- JP2023552851A5 JP2023552851A5 JP2023535529A JP2023535529A JP2023552851A5 JP 2023552851 A5 JP2023552851 A5 JP 2023552851A5 JP 2023535529 A JP2023535529 A JP 2023535529A JP 2023535529 A JP2023535529 A JP 2023535529A JP 2023552851 A5 JP2023552851 A5 JP 2023552851A5
- Authority
- JP
- Japan
- Prior art keywords
- chain
- seq
- antibody
- cancer
- terminus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911253241 | 2019-12-09 | ||
| CN202011427863.9A CN113135996A (zh) | 2019-12-09 | 2020-12-09 | 一种双特异抗体及其应用 |
| CN202011427863.9 | 2020-12-09 | ||
| PCT/CN2021/094672 WO2022121239A1 (zh) | 2019-12-09 | 2021-05-19 | 一种双特异性抗体及其应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023552851A JP2023552851A (ja) | 2023-12-19 |
| JP2023552851A5 true JP2023552851A5 (enExample) | 2024-01-15 |
| JP7818838B2 JP7818838B2 (ja) | 2026-02-24 |
Family
ID=76809347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023535529A Active JP7818838B2 (ja) | 2019-12-09 | 2021-05-19 | 二重特異性抗体およびその適用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240043567A1 (enExample) |
| EP (1) | EP4261231A4 (enExample) |
| JP (1) | JP7818838B2 (enExample) |
| CN (1) | CN113135996A (enExample) |
| WO (1) | WO2022121239A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110054701B (zh) * | 2019-04-17 | 2022-12-27 | 中国医学科学院血液病医院（血液学研究所） | 一种基于间充质干细胞的抗肿瘤靶向给药系统及其应用 |
| CN113135996A (zh) * | 2019-12-09 | 2021-07-20 | 启愈生物技术(上海)有限公司 | 一种双特异抗体及其应用 |
| JP7642857B2 (ja) * | 2021-04-22 | 2025-03-10 | 広東菲鵬制▲薬▼股▲ふん▼有限公司 | 二重特異性多機能性融合ポリペプチド |
| US20240294640A1 (en) * | 2021-06-02 | 2024-09-05 | Qure Biotechnology (Shanghai) Co., Ltd. | Anti-cd3 antibody variant, fusion protein, and application |
| WO2023006082A1 (zh) * | 2021-07-30 | 2023-02-02 | 启愈生物技术(上海)有限公司 | 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用 |
| CN116284430A (zh) * | 2021-07-30 | 2023-06-23 | 广东菲鹏制药股份有限公司 | 靶向肿瘤的il15融合蛋白及其应用 |
| WO2023020315A1 (zh) * | 2021-08-19 | 2023-02-23 | 南京吉盛澳玛生物医药有限公司 | 靶向pd-l1/pd-1的抗体及其应用 |
| CN113817065B (zh) * | 2021-09-06 | 2023-04-18 | 深圳市乐土生物医药有限公司 | 一种抗her2的多肽及其用途 |
| CN116143942A (zh) * | 2021-09-09 | 2023-05-23 | 启愈生物技术(上海)有限公司 | 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用 |
| CN116178565A (zh) * | 2021-09-24 | 2023-05-30 | 广东菲鹏制药股份有限公司 | 一种双特异性多肽复合物 |
| TW202321315A (zh) * | 2021-09-24 | 2023-06-01 | 大陸商廣東菲鵬製藥股份有限公司 | 白介素15及其受體的多肽複合物 |
| CN116496408A (zh) * | 2022-01-21 | 2023-07-28 | 广东菲鹏制药股份有限公司 | 白细胞介素21及其受体复合物 |
| CN115246885B (zh) * | 2022-06-30 | 2023-10-24 | 盛禾(中国)生物制药有限公司 | 一种双特异性抗体及其应用 |
| CN116178546B (zh) * | 2022-10-13 | 2024-06-18 | 深圳市百士通科技开发有限公司 | 一种多功能重组抗体及其制备方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| EP2619229B1 (en) | 2010-09-21 | 2016-04-06 | Altor BioScience Corporation | Multimeric il-15 soluble fusion molecules and methods of making and using same |
| EP2537933A1 (en) * | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| WO2014014796A1 (en) * | 2012-07-18 | 2014-01-23 | Eli Lilly And Company | Multi-specific igg-(fab)2 constructs containing t-cell receptor constant domains |
| CA2925677A1 (en) * | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | Bispecific her2 antibodies and methods of use |
| AU2014377106B2 (en) * | 2014-01-08 | 2019-10-03 | Jiangsu Hengrui Medicine Co., Ltd. | IL-15 heterodimeric protein and uses thereof |
| LT3235830T (lt) * | 2014-12-19 | 2020-12-28 | Jiangsu Hengrui Medicine Co., Ltd. | Interleukino 15 baltymų kompleksas ir jo naudojimas |
| WO2017205726A1 (en) * | 2016-05-27 | 2017-11-30 | Altor Bioscience Corporation | Construction and characterization of multimeric il-15-based molecules with cd3 binding domains |
| AU2018291497A1 (en) | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
| MA50188A (fr) | 2017-09-22 | 2021-06-02 | Wuxi Biologics Ireland Ltd | Nouveaux complexes polypeptidiques bispécifiques |
| US11168138B2 (en) * | 2018-03-26 | 2021-11-09 | Altor Bioscience, Llc | Anti-PDL1, IL-15 and TGF-beta receptor combination molecules |
| CA3097593A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| JP2021520829A (ja) * | 2018-04-18 | 2021-08-26 | ゼンコア インコーポレイテッド | ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質 |
| KR20210003813A (ko) * | 2018-04-18 | 2021-01-12 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 LAG-3 항원 결합 도메인을 함유하는 LAG-3 표적화 이종이량체 융합 단백질 |
| CN110437339B (zh) * | 2018-05-04 | 2021-08-13 | 免疫靶向有限公司 | 一种以白介素15为活性成分的融合蛋白型药物前体 |
| EP3988574A4 (en) * | 2019-02-03 | 2022-10-12 | Shanghai Bao Pharmaceuticals Co., Ltd. | AGAINST HER2 BI-SPECIFIC ANTIBODIES AND THEIR USE |
| WO2020168554A1 (zh) * | 2019-02-22 | 2020-08-27 | 武汉友芝友生物制药有限公司 | 改造的Fc片段，包含其的抗体及其应用 |
| CN113135996A (zh) * | 2019-12-09 | 2021-07-20 | 启愈生物技术(上海)有限公司 | 一种双特异抗体及其应用 |
-
2020
- 2020-12-09 CN CN202011427863.9A patent/CN113135996A/zh active Pending
-
2021
- 2021-05-19 EP EP21901953.6A patent/EP4261231A4/en active Pending
- 2021-05-19 US US18/256,679 patent/US20240043567A1/en active Pending
- 2021-05-19 WO PCT/CN2021/094672 patent/WO2022121239A1/zh not_active Ceased
- 2021-05-19 JP JP2023535529A patent/JP7818838B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7818838B2 (ja) | 二重特異性抗体およびその適用 | |
| US12269885B2 (en) | Anti-PD-L1/VEGF bifunctional antibody and use thereof | |
| KR102629503B1 (ko) | ＴＧＦ－β 수용체를 함유하는 융합 단백질 및 이의 약학적 용도 | |
| US11292841B2 (en) | Anti-PD-1 nano-antibody and application thereof | |
| CN105121474B (zh) | 融合免疫调节蛋白及其制备方法 | |
| EP4406965A1 (en) | Interleukin-2 mutant and fusion protein thereof | |
| WO2018233574A1 (zh) | 一种抗pd-l1人源化纳米抗体及其应用 | |
| CN109575140A (zh) | 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途 | |
| WO2023046156A1 (en) | Il-2 variants and fusion proteins thereof | |
| JP7766672B2 (ja) | ＴＧＦ－β ＲＩＩ突然変異体及びその融合タンパク質 | |
| JP2023526448A (ja) | ヒトｉｌ－１５変異体およびその使用 | |
| CN114195894B (zh) | 一种靶向4-1bb的抗体及其应用 | |
| CA3134006A1 (en) | Multispecific agents for treatment of cancer | |
| WO2021219127A1 (zh) | 一种靶向her2和pd-1的双特异性抗体及其应用 | |
| AU2023205911A1 (en) | Gamma delta t-cell-binding polypeptides and uses thereof | |
| CN103172741B (zh) | 全人源抗egfr抗体 | |
| CN121554592A (zh) | 靶向c-Met的多特异性抗体 | |
| CN115246885A (zh) | 一种双特异性抗体及其应用 | |
| CN115181180B (zh) | 抗人程序性死亡配体-1（pd-l1）的抗体及其应用 | |
| WO2024199458A1 (en) | Il-2 variants with improved stability and compositions thereof | |
| KR20130057959A (ko) | 항 ｈｅｒ2 단일클론항체와 ｉｌ-2를 포함하는 융합 단일클론 항체 및 이를 포함하는 암치료용 조성물 | |
| CN118894943A (zh) | 靶向密蛋白的双特异性抗体 | |
| CN118894944A (zh) | 抗密蛋白双特异性抗体 | |
| HK40060665A (en) | Anti-pd-l1/vegf bifunctional antibody and use thereof |